AKTS earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -40.67. Updated 2026-07-23.
Aktis Oncology (AKTS) Research Hub
Aktis Oncology (AKTS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 23.3 USD (-3.16%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -40.67, market cap 1.31B. This hub links to the full technical, earnings and options research available for AKTS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.3 USD (-3.16%) |
| 52-week range | 20.5 USD – 34.19 USD |
| Trend regime | Range |
| 14-day RSI | 46.6 (Neutral) |
| Trailing P/E | -40.67 |
| Market cap | 1.31B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AKTS
Covered Call on AKTS: how it works, illustrative setup around the real 23.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AKTS: how it works, illustrative setup around the real 23.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AKTS: how it works, illustrative setup around the real 23.3 USD price, max profit/loss, breakeven and when to use it. Educational.
AKTS technical analysis: range, last 23.3 USD, RSI 46.6, 52w range 20.5 USD–34.19 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AKTS in?
Aktis Oncology (AKTS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AKTS in an uptrend or downtrend?
As of 2026-09-11, AKTS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AKTS's trailing P/E ratio?
AKTS's trailing P/E is -40.67, with a market cap of 1.31B. See the earnings research page for full valuation detail.
When does AKTS next report earnings?
AKTS is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.44 USD.